Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.

Sees FY17 revenues and EPS at high end of range.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c